# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

- acknowledge government support

## BACKGROUND

- introduce necrotizing enterocolitis
- describe its effects and current treatment limitations

## SUMMARY

- introduce AHR agonist compounds
- define compound of formula (I)
- specify X₁ and Y₁
- specify R₁
- specify R₂
- specify R₃ and R₄
- provide examples of compounds of formula (I)
- introduce compound of formula (II)
- define compound of formula (II)
- provide examples of compounds of formula (II)
- introduce compound of formula (III)
- define compound of formula (III)
- provide examples of compounds of formula (III)

## DETAILED DESCRIPTION

- introduce patent application structure
- describe purpose of detailed description
- provide background on aryl hydrocarbon receptor ligands
- motivate use of AHR agonists for inflammatory disorders
- describe administration of AHR agonists to pregnant mothers
- introduce compounds of formula (I-III) and their analogues

### A. Compounds

- introduce compounds of formula (I)
- define variables in formula (I)
- provide specific embodiments of formula (I)
- introduce compounds of formula (II)
- define variables in formula (II)
- provide specific embodiments of formula (II)
- introduce compounds of formula (III)
- define variables in formula (III)
- provide specific embodiments of formula (III)
- describe pharmaceutically acceptable salts

### B. Methods of Treatment

- introduce methods of treating inflammatory disorders
- describe activation of AHR
- define inflammatory disorders
- provide examples of inflammatory disorders
- describe treatment of necrotizing enterocolitis
- define subject
- describe human subjects
- describe animal subjects
- define infant
- define newborn
- define premature infant
- describe treatment of human subjects
- describe enteral administration
- define effective amount
- describe combination therapy
- introduce additional therapeutic agents
- describe administration of combination therapy
- describe simultaneous administration
- describe sequential administration
- describe synergistic effect
- define synergy index
- describe antagonism
- describe additivity
- describe synergistically effective amount
- describe prophylactic treatment
- describe reducing risk of NEC
- describe reducing severity of NEC

### C. Infant Nutritional Formula Comprising Aryl Hydrocarbon Receptor (AHR) Agonists for the Prevention and Treatment of Inflammatory Disorders

- introduce infant nutritional formula
- describe formula composition
- specify formula forms
- describe liquid formulation
- provide examples of commercial formulas
- describe enteral administration

### D. Maternal Administration of an Aryl Hydrocarbon Receptor (AHR) Agonist

- describe method for preventing inflammatory disorders

### E. Pharmaceutical Compositions and Administration

- introduce pharmaceutical composition
- describe pharmaceutically acceptable salts
- provide examples of acid addition salts
- provide examples of base addition salts
- describe pharmaceutical composition formulation
- specify modes of administration
- describe systemic administration
- describe topical administration
- describe timed-release forms
- specify routes of administration
- describe parenteral delivery
- describe transmucosal administration
- describe nasal or inhalation delivery
- specify effective amounts
- describe pharmaceutical composition preparation
- describe oral administration preparations
- describe tablet preparation
- describe dragee preparation
- describe capsule preparation

### F. Definitions

- define terms generically
- introduce compound definitions
- define substituted and substituent
- explain substituent groups
- define independently selected
- introduce "a" and "an" notation
- define R-substituted
- explain named R groups
- describe compound limitations
- define substituent groups
- introduce hydrocarbon
- define alkyl
- explain saturated hydrocarbon groups
- define branched alkyl
- introduce lower and higher alkyl
- define alkyl group substituents
- explain substituted alkyl
- introduce heteroalkyl
- define heteroalkyl groups
- explain cyclic and cycloalkyl
- define cycloalkylalkyl
- introduce cycloheteroalkyl
- define cycloheteroalkyl ring systems
- explain fused ring systems
- define cycloalkyl and heterocycloalkyl
- introduce unsaturated hydrocarbon
- define homoalkyl
- define alkenyl
- define cycloalkenyl
- define alkynyl
- define alkylene
- define heteroalkylene
- define aryl
- define heteroaryl
- define arylene and heteroarylene
- define haloaryl
- define ring structure
- define bond representation
- define point of attachment
- define absent atom
- list substituents for alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl
- list substituents for aryl and heteroaryl
- define acyl
- define alkoxyl and alkoxy
- define alkoxyalkyl
- define aryloxyl
- provide examples of aryl and heteroaryl groups
- provide examples of alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl groups
- provide examples of alkylene and heteroalkylene groups
- provide examples of arylene and heteroarylene groups
- provide examples of ring structures
- provide examples of substituents for alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl
- provide examples of substituents for aryl and heteroaryl
- provide additional examples of substituents
- define aralkyl
- define aralkyloxyl
- define alkoxycarbonyl
- define aryloxycarbonyl
- define aralkoxycarbonyl
- define carbamoyl
- define alkylcarbamoyl
- define dialkylcarbamoyl
- define carbonyldioxyl
- define acyloxyl
- define amino
- define aminoalkyl
- define alkylamino
- define dialkylamino
- define trialkylamino
- define acylamino
- define aroylamino
- define carbonyl
- define carboxyl
- define cyano
- define halo
- define hydroxyl
- define hydroxyalkyl
- define mercapto
- define oxo
- define nitro
- define thio
- define sulfate
- define sulfide
- define sulfone
- define sulfoxide
- define ureido

## EXAMPLES

- provide guidance for practicing embodiments

### Example 1

- define abbreviations
- introduce NEC
- motivate maternal-fetal signaling
- summarize current dogma
- limitations of current dogma
- application of AHR signaling
- introduce AHR ligand I3C
- summarize NEC development
- role of TLR4 in NEC
- expression of TLR4 in premature infants
- activation of TLR4 by luminal bacteria
- mucosal death and bacterial translocation
- current preventive strategies
- emerging evidence for in utero process
- link between maternal diet and premature birth
- scope of the presently disclosed subject matter
- focus on AHR signaling
- AHR activation in the newborn gut
- reduction of TLR4 signaling
- administration of I3C during pregnancy
- induction of Cyp1a1 in the small intestine
- confirmation of AHR activation
- reduction of NEC severity
- reduced histological injury
- reduced expression of IL6
- reduced intestinal epithelial apoptosis
- presence of AHR ligands in maternal fluids
- induction of Cyp1a1 in IEC-6 enterocytes
- reduction of TLR4 signaling in the pup intestine
- expression of AHR in the intestine
- reduction of AHR in infants with NEC
- reduction of AHR in mice with NEC
- reduction of AHR in piglets with NEC
- deletion of Ahr globally
- deletion of Ahr from the intestinal epithelium
- deletion of Ahr from the myeloid compartment
- development of more severe NEC in Ahr−/− mice
- requirement of AHR signaling on the intestinal epithelium
- administration of I3C to neonatal mice
- reduction of NEC severity in wild-type mice
- no protective effect in Ahr−/− mice
- moderate protective effect in AhrΔlys mice
- reduction of TLR4 signaling and expression
- discovery of AHR ligand A18
- introduce necrotizing enterocolitis
- discuss pathogenesis and urgency
- propose AHR signaling in intestinal epithelium
- describe mechanism of AHR activation
- discuss therapeutic potential of AHR ligands
- introduce AHR ligand A18
- discuss chemical mechanism of AHR binding
- highlight limitations of A18 for clinical use
- discuss potential impact on clinical medicine
- introduce methods section
- describe mouse model
- describe discovery of AHR ligands
- describe induction of NEC in mice
- describe induction of NEC in piglets
- describe mice endotoxemia model
- describe AHR induction in pregnant mice
- describe harvest and culture of enteroids
- describe human ileal sample collection and explant culture
- describe immunofluorescence staining
- describe RNA isolation and quantification
- describe lamina propria cell isolation and flow cytometry
- describe intestinal permeability assay
- describe statistical analysis
- detail mouse model
- detail AHR ligand discovery
- detail NEC induction in mice
- detail NEC induction in piglets
- detail mice endotoxemia model
- detail AHR induction in pregnant mice
- detail enteroid harvest and culture
- detail human ileal sample collection
- detail immunofluorescence staining
- detail RNA isolation and quantification
- detail lamina propria cell isolation
- detail flow cytometry
- detail intestinal permeability assay
- detail statistical analysis

### Example 2

- introduce necrotizing enterocolitis (NEC)
- describe NEC development
- motivate AHR activation
- identify AHR agonist
- describe A18
- synthesize analogues
- identify compound 169
- describe SAR studies
- prepare representative compounds
- discuss administration to pregnant mothers
- introduce general considerations
- describe reaction conditions
- outline purification methods
- describe analytical methods
- introduce synthesis
- prepare 5-fluoro-1,2-diaminobenzene
- prepare 5-fluoro-2-thiobenzimidazole
- prepare 5-methyl-2-thiobenzimidazole
- prepare 5-cyano-2-thiobenzimidazole
- prepare 2,3-dimethylpyridine N-oxide
- prepare 2,3-dimethyl-4-nitropyridine N-oxide
- prepare 2,3-dimethyl-4-trifluoroethoxypyridine N-oxide
- prepare 2,3-dimethyl-4-methoxypyridine N-oxide
- prepare 2,3-dimethyl-4-ethoxypyridine N-oxide
- prepare 2,3-dimethyl-4-phenoxypyridine N-oxide
- prepare 2,3-dimethyl-4-benzyloxypyridine N-oxide
- prepare 2-methylenehydroxy-3-methyl-4-trifluoroethoxypyridine
- prepare 2-methylenehydroxy-3-methyl-4-methoxypyridine
- extract product
- purify product
- characterize product
- compare to literature
- provide reference
- prepare 2-methylenehydroxy-3-methyl-4-ethoxypyridine
- prepare 2-methylenehydroxy-3-methyl-4-phenoxypyridine
- prepare 2-methylenehydroxy-3-methyl-4-benzyloxypyridine
- prepare 5-fluoro-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyrid
- prepare 5-methyl-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyrid
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- synthesize intermediate
- prepare 5-fluoro-2-(((3-methyl-4-ethoxypyridin-2-yl)methyl)thio
- prepare 5-fluoro-2-(((3-methyl-4-phenoxypyridin-2-yl)methyl)thio
- prepare 5-fluoro-2-(((3-methyl-4-benzyloxypyridin-2-yl)methyl)th
- prepare 5-methyl-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin
- prepare 5-methyl-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin
- describe NMR spectra
- describe NMR spectra
- describe NMR spectra
- describe NMR spectra
- describe HRMS data
- describe HRMS data
- describe HRMS data
- describe HRMS data
- describe IR spectra
- describe IR spectra
- describe IR spectra
- describe IR spectra
- describe reaction conditions
- describe reaction conditions
- introduce preparation methods
- prepare 5-fluoro-2-(((3-methyl-4-methoxypyridin-2-yl)methyl)sulfony
- prepare 5-fluoro-2-(((3-methyl-4-ethoxypyridin-2-yl)methyl)sulfony
- prepare 5-fluoro-2-(((3-methyl-4-phenoxypyridin-2-yl)methyl)sulfony
- prepare 5-fluoro-2-(((3-methyl-4-benzyloxypyridin-2-yl)methyl)sul
- prepare 5-fluoro-2-(((3-methyl-4-(2,2,2)-trifluoroethoxypyrid
- prepare 5-fluoro-2-(((1-oxo-3-methyl-4-phenoxypyridin-2-yl
- describe NMR spectra
- describe HRMS spectra
- describe IR spectra
- describe mp values
- describe reaction conditions
- describe purification methods
- describe quenching methods
- describe extraction methods
- describe washing methods
- describe drying methods
- prepare 2-oxoquinazoline
- prepare 2-thioquinazoline
- prepare 2-chloromethylbenzimidazole
- prepare 4-(((1H-benzo[d]imidazol-2-yl)methyl)thio)quinazoline
- characterize 4-(((1H-benzo[d]imidazol-2-yl)methyl)thio)quinazoline
- prepare 4-(((1H-benzo[d]imidazol-2-yl)methoxy)quinazoline
- purify 4-(((1H-benzo[d]imidazol-2-yl)methoxy)quinazoline
- characterize 4-(((1H-benzo[d]imidazol-2-yl)methoxy)quinazoline
- prepare 4-((1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)quinazoline
- purify 4-((1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)quinaz
- characterize 4-((1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)quinazoline
- report spectral data
- prepare quinazoline derivatives
- synthesize 4-((1-benzyl-1H-benzo[d]imidazol-2-yl)methoxy)quin
- characterize 4-((1-benzyl-1H-benzo[d]imidazol-2-yl)methoxy)quin
- prepare 2-ethyl-4-(((1H-benzo[d]imidazol-2-yl)methoxy)quinazoline
- synthesize 2-ethyl-4-(((1H-benzo[d]imidazol-2-yl)methoxy)quinaz
- characterize 2-ethyl-4-(((1H-benzo[d]imidazol-2-yl)methoxy)quinaz
- prepare 2-hydroxy-4-(((1H-benzo[d]imidazol-2-yl)methoxy)quinaz
- synthesize 2-hydroxy-4-(((1H-benzo[d]imidazol-2-yl)methoxy)quin
- characterize 2-hydroxy-4-(((1H-benzo[d]imidazol-2-yl)methoxy)quin
- prepare 2-ethyl-4-((1-benzyl-1H-benzo[d]imidazol-2-yl)meth
- synthesize 2-ethyl-4-((1-benzyl-1H-benzo[d]imidazol-2-yl)m
- characterize 2-ethyl-4-((1-benzyl-1H-benzo[d]imidazol-2-yl)m
- prepare 2-trifluoromethyl-4-(((1H-benzo[d]imidazol-2-yl)thiom
- synthesize 2-trifluoromethyl-4-(((1H-benzo[d]imidazol-2-yl)th
- characterize 2-trifluoromethyl-4-(((1H-benzo[d]imidazol-2-yl)th

### Example 3

- introduce AHR activation
- motivate AHR agonist search
- identify A18 as AHR agonist
- describe A18 administration results
- synthesize and test A18 analogues
- discuss compound #169, #243, #247 results
- describe in vivo testing of compounds
- synthesize and test additional analogues
- describe compound #263 results
- outline mouse experiment methods
- describe RNA isolation and quantification

